Zevra Therapeutics appoints Alvin Shih, M.D. to board of directors

ZEVRA THERAPEUTICS, INC.

Dr. Alvin Shih appointed as Class III director effective January 20, 2024.
Shih has rare disease experience, former COO of Pfizer's Rare Disease Research Unit.
Initial option grant of 58,800 shares vesting over 3 years, annual retainer $40,000.
Shih will receive additional option of 39,200 shares annually while serving on board.
No family relationships or transactions requiring disclosure under Item 404(a).

item 5.02

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Alvin Shih, M.D.

director

ZVRA · ZEVRA THERAPEUTICS, INC.

Effective: 2024-01-20
Filed: January 23, 2024, 6:59 PM ET

On January 20, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Alvin Shih, M.D. to serve as a director of the Company, effective immediately.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 1.0

Alvin Shih, M.D. was appointed as director at ZEVRA THERAPEUTICS, INC..

Action: appointed
Role: director

Exact text from the filing

On January 20, 2024, the board of directors (the “Board”) of Zevra Therapeutics, Inc. (the “Company”) appointed Alvin Shih, M.D. to serve as a director of the Company, effective immediately.

View on SEC.gov

ZEVRA THERAPEUTICS, INC. filing history →

Source: SEC EDGAR

accession 0001437749-24-001909

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.